![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Safety and Efficacy of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B
|
|
|
Reported by Jules Levin
EASL 2012
Robert Perrillo1, Maria Buti Ferret2, Francois Durand3, Michael Charlton4, Adrian Gadano5, Guido Cantisani6, Kimberly Brown7, Wenhua Hu7, Juan Carlos Lopez-Talavera7, Cyril Llamoso7
1Hepatology Division, Baylor University Medical Center, Dallas, TX, USA; 2. Liver Unit, Hospital General Universitario Vall d'Hebron and Ciberehd del Instituto Carlos III Barcelona, Spain; 3. Service d'Hepatologie, INSERM CRB3, University of Paris VII, Hopital, Beaujon, Clichy 92 110, France; 4. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA; 5. Sección Hepatología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; 6. Liver Transplantation Group, Complexo Hospitalar Santa Casa, Porto Alegre-RS, Brazil; Department of Surgery, School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre-RS, Brazil; 7. Research and Development, Bristol-Myers Squibb Company, Wallingford, CT, USA
![EASL1.gif](../images/050412/050412-10/EASL1.gif)
![EASL2.gif](../images/050412/050412-10/EASL2.gif)
![EASL3.gif](../images/050412/050412-10/EASL3.gif)
![EASL4.gif](../images/050412/050412-10/EASL4.gif)
![EASL5.gif](../images/050412/050412-10/EASL5.gif)
![EASL6.gif](../images/050412/050412-10/EASL6.gif)
![EASL7.gif](../images/050412/050412-10/EASL7.gif)
![EASL8.gif](../images/050412/050412-10/EASL8.gif)
![EASL9.gif](../images/050412/050412-10/EASL9.gif)
![EASL10.gif](../images/050412/050412-10/EASL10.gif)
![EASL11.gif](../images/050412/050412-10/EASL11.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|